69 related articles for article (PubMed ID: 8742630)
1. [Overview of clinical studies with ipriflavone].
Attila BK
Acta Pharm Hung; 1995 Nov; 65(6):223-8. PubMed ID: 8742630
[TBL] [Abstract][Full Text] [Related]
2. [A new treatment possibility for osteoporosis with osteochin (ipriflavone) tablets].
Bossányi A; Bucsi L
Magy Traumatol Orthop Helyreallito Seb; 1989; 32(2):109-15. PubMed ID: 2570885
[TBL] [Abstract][Full Text] [Related]
3. [Place of ipriflavone in the therapy of osteoporosis].
Zsuzsanna B
Acta Pharm Hung; 1995 Nov; 65(6):229-32. PubMed ID: 8742631
[TBL] [Abstract][Full Text] [Related]
4. [The ipriflavone story].
György L; Mihály N; Marian EP; István H
Acta Pharm Hung; 1995 Nov; 65(6):191-4. PubMed ID: 8742624
[TBL] [Abstract][Full Text] [Related]
5. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
[TBL] [Abstract][Full Text] [Related]
6. [Effects of ipriflavone on bone loss induced by GnRH analog].
Pellicano M; Morgera R; Affinito P; Di Carlo C; Napolitano V; Merlino P; Tremolaterra F; Palomba S; Nappi C
Minerva Ginecol; 1996 Oct; 48(10):435-9. PubMed ID: 9005368
[TBL] [Abstract][Full Text] [Related]
7. Ipriflavone: an important bone-building isoflavone.
Head KA
Altern Med Rev; 1999 Feb; 4(1):10-22. PubMed ID: 9988779
[TBL] [Abstract][Full Text] [Related]
8. Ipriflavone modulates IGF-I but is unable to restore bone in rats.
Deyhim F; Smith BJ; Soung DY; Juma S; Devareddy L; Arjmandi BH
Phytother Res; 2005 Feb; 19(2):116-20. PubMed ID: 15852487
[TBL] [Abstract][Full Text] [Related]
9. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
10. [Experience with ipriflavone therapy in postmenopausal osteoporosis].
Szántó F
Orv Hetil; 1997 Nov; 138(44):2801-3. PubMed ID: 9411349
[TBL] [Abstract][Full Text] [Related]
11. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
12. Ipriflavone not effective for osteoporosis.
Harv Womens Health Watch; 2001 Jun; 8(10):5. PubMed ID: 11439282
[No Abstract] [Full Text] [Related]
13. Ipriflavone.
Altern Med Rev; 2000 Jun; 5(3):260-3. PubMed ID: 10869105
[No Abstract] [Full Text] [Related]
14. Proceedings from a symposium of basic research on ipriflavone (Osten). Yokohama, Japan. January 18, 1992.
Calcif Tissue Int; 1992; 51 Suppl 1():S1-34. PubMed ID: 1358419
[No Abstract] [Full Text] [Related]
15. [Application of dietary supplement to periodontal disease and osteoporosis].
Takemura A; Nishida M
Clin Calcium; 2006 Feb; 16(2):354- 58. PubMed ID: 16465041
[TBL] [Abstract][Full Text] [Related]
16. Closing Remarks.
Reed E
Oncologist; 1996; 1(4):276-277. PubMed ID: 10388002
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
18. [High performance liquid chromatographic method for the determination of ipriflavone in serum and its pharmacokinetic study in healthy volunteers].
Ma XH; Xu Y; Liu TP
Yao Xue Xue Bao; 1997 Jun; 32(6):470-2. PubMed ID: 11596332
[TBL] [Abstract][Full Text] [Related]
19. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis.
Jones G; Hogan DB; Yendt E; Hanley DA
CMAJ; 1996 Oct; 155(7):955-61. PubMed ID: 8837546
[TBL] [Abstract][Full Text] [Related]
20. [Phytoestrogens].
Zittermann A
Zentralbl Gynakol; 2003 Jun; 125(6):195-201. PubMed ID: 14556117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
